Source comparison
Comparison: CJC-1295 vs Other Long-Acting GH Secretagogues
The table below compares CJC-1295 with DAC against other peptides and pharmacologic agents used to elevate GH in research contexts, focusing on half-life, documented study duration, and receptor mechanism. CJC-1295 (with DAC) 6–8 days 12 weeks (McGill 2012) GH
This comparison does not assign a generated winner or score.
- The table below compares CJC-1295 with DAC against other peptides and pharmacologic agents used to elevate GH in research contexts, focusing on half-life, documented study duration, and receptor mechanism.
- CJC-1295 (with DAC)
- 6–8 days
- 12 weeks (McGill 2012)
- GHRH receptor agonist with albumin binding
- No. Longest trial 12 weeks
- Sustained GH elevation confirmed short-term; long-term human data absent
- Tesamorelin
- 26–38 minutes
- 26 weeks (HIV lipodystrophy trials)
- GHRH analog, no DAC modification
- Yes. 26-week data published, 52-week extension ongoing
- More safety data available but requires daily dosing
- Ipamorelin
- ~2 hours
- 8 weeks (small-scale trials)
- Ghrelin receptor agonist, pulsatile secretion
- No. Limited to 8-week trials
- Short half-life limits long-term study practicality
- MK-677 (Ibutamoren)
- 24 hours
- 12 months (elderly cohort, JCEM 2008)
- Ghrelin mimetic, oral bioavailability
- Yes. 12-month human data exists
- Oral convenience; year-long safety documented in elderly adults
- Recombinant hGH (Norditropin, Genotropin)
- 3–4 hours (subcutaneous)
- Decades (clinical use since 1980s)
- Direct GH replacement, not secretagogue
- Extensive. Pediatric and adult long-term registries
- Gold standard but requires daily injection; cost and regulation barriers
- CJC-1295's appeal lies in its dosing convenience. Twice weekly instead of daily. But that same extended half-life makes it the least-studied in terms of duration. MK-677 has year-long human data but different mechanism and side effect profile (increased appetite, mild insulin resistance in some cohorts). Tesamorelin sits between the two: better safety documentation than CJC-1295 but still shorter-acting than DAC-modified compounds.